Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

WuXi AppTec (HK: 2359) and WuXi Biologics (HK: 2269) rose 4% and 3.5%, respectively, in Hong Kong trade, extending gains into ...

Big pharmaceutical companies are seeing Chinese biotech as the disruptors. Read more at straitstimes.com. Read more at ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

The company PFE announced late Monday a license agreement with China-based 3SBio Inc. HK:1530 to develop, make and sell an antibody — SSGJ-707 — that targets PD-1 and VEGF, which suppresses ...